ASLAN Keeps Eye On Maximizing Values After Fundraising
This article was originally published in PharmAsia News
ASLAN has closed a Series C round involving some new investors that puts the Singapore venture in a more comfortable financial position and may allow it to complete pivotal trials for its lead oncology project. But its CEO says the main focus will continue to be on maximizing asset values.
Register for our free email digests: